Royersford, PA

Vice President of Value Evidence and Outcomes, GlaxoSmithKline

Represented: Industry
Term ended August 2020

Marcia Rupnow, PhD, is Vice President of Value Evidence and Outcomes at GlaxoSmithKline, responsible for overseeing the health economics and outcomes research (HEOR) strategy and execution across a portfolio of products in cardiovascular, metabolics, renal, rare diseases, and neurosciences. Her responsibilities span inputs into early discovery efforts, as well as post-launch and lifecycle management support. During her professional career, Dr. Rupnow conceptualized and implemented extensive outcomes research initiatives across multiple therapeutic areas. She has a unique breadth of experience in both pharmaceutical and medical device sectors, including research on device-biologic combination products. She has co-authored over 50 publications in peer-reviewed journals and more than 100 poster/podium presentations at scientific meetings. Highlights of her work include patient-reported outcomes and caregiver burden in psychiatric, neurologic and metabolic conditions, quality measures, and major research initiatives with multi-stakeholder collaboration (employer, payer, providers, and patients). Dr. Rupnow served on the PCORI Advisory Panel on Assessment of Prevention, Diagnosis, and Treatment Options from 2013 to 2016.

Conflicts of Interest

As of March 29, 2017

  • GlaxoSmithKline, employee (self)
  • Johnson & Johnson, stock (self)
  • Johnson & Johnson, employee (spouse)
  • Bristol Myers Squibb, stock (spouse)


Person Type
Panel / Committee